WP
DNTH icon

Woodline Partners’s Dianthus Therapeutics DNTH Stock Holding History

Woodline Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.4M Buy
433,457
+220,370
+103% +$12.8M 0.14% 195
2025
Q4 		$8.78M Buy
213,087
+170,389
+399% +$6.61M 0.03% 492
2025
Q3 		$1.68M Sell
42,698
-357,806
-89% -$9.14M 0.01% 743
2025
Q2 		$7.46M Buy
400,504
+100,000
+33% +$1.88M 0.04% 486
2025
Q1 		$5.45M Hold
300,504
– – 0.04% 484
2024
Q4 		$6.55M Buy
300,504
+50,000
+20% +$1.29M 0.04% 430
2024
Q3 		$6.86M Buy
250,504
+171
+0.1% +$4.76K 0.06% 348
2024
Q2 		$6.48M Buy
+250,333
New +$6.02M 0.06% 308
2022
Q4 		– Sell
-81,559
Closed -$1.84M – 779
2022
Q3 		$1.84M Buy
81,559
+23,235
+40% +$636K 0.03% 477
2022
Q2 		$1.12M Buy
58,324
+8,545
+17% +$211K 0.02% 504
2022
Q1 		$2.31M Buy
49,779
+33,249
+201% +$1.82M 0.04% 364
2021
Q4 		$1.17M Sell
16,530
-15,699
-49% -$1.58M 0.02% 493
2021
Q3 		$3.75M Buy
+32,229
New +$3.75M 0.06% 300

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners's DNTH Position: Q1 2026 in Review

Woodline Partners increased its Dianthus Therapeutics (DNTH) stake by 103% in Q1 2026, buying an estimated $12.8M and bringing the position to 433,457 shares worth $36.4M. The position accounts for 0.14% of the portfolio, ranked #195.

Woodline Partners first reported a position in DNTH in Q3 2021 and has held it in 13 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Woodline Partners held 433,457 shares of Dianthus Therapeutics worth $36.4M as of Q1 2026.
  • Woodline Partners bought 220,370 Dianthus Therapeutics shares in Q1 2026, an estimated $12.8M.
  • Dianthus Therapeutics made up 0.14% of Woodline Partners's portfolio in Q1 2026, its #195 holding.
  • Woodline Partners first reported a position in Dianthus Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.